Gossamer Bio Files Automatic Mixed Securities Shelf
Gossamer Bio files automatic mixed securities shelf
Trade with 70% Backtested Accuracy
Analyst Views on GOSS
About GOSS
About the author
Gossamer Bio (GOSS) Options Trading Volume Hits 36,131 Contracts, 73.1% of Average Daily Volume
- Active Options Trading: Gossamer Bio Inc (GOSS) recorded an options trading volume of 36,131 contracts today, equivalent to approximately 3.6 million shares, representing 73.1% of its average daily trading volume of 4.9 million shares over the past month, indicating strong market interest in its future performance.
- Put Options Highlighted: Notably, the $2 strike put option expiring on February 20, 2026, saw a significant volume of 12,338 contracts traded today, representing about 1.2 million underlying shares, reflecting investor expectations regarding potential downside risks for GOSS's stock price.
- Novanta Options Activity: Concurrently, Novanta Inc (NOVT) experienced an options trading volume of 3,468 contracts, equivalent to approximately 346,800 shares, which accounts for 72.7% of its average daily trading volume of 476,875 shares over the past month, showcasing ongoing market interest in its stock.
- Call Options Trading: Within NOVT's trading, the $140 strike call option expiring on February 20, 2026, stood out with a trading volume of 1,724 contracts today, representing around 172,400 underlying shares, indicating investor optimism regarding its future price potential.
Gossamer Bio Grants 212,500 Stock Options to Employees Under 2023 Inducement Plan
- Incentive Plan Implementation: Gossamer Bio's Compensation Committee approved the grant of 212,500 non-qualified stock options to three non-executive employees, aimed at attracting talent and enhancing employee loyalty in accordance with Nasdaq Listing Rule 5635(c)(4).
- Option Details: The options have an exercise price of $2.74 per share, equal to the closing price on January 5, 2026, with a ten-year term and vesting over four years, reflecting the company's commitment to long-term employee contributions.
- Employee Incentive Mechanism: By providing stock options upon employee onboarding, Gossamer Bio not only enhances employee engagement but also potentially strengthens team stability, which could drive the company's competitive edge in the pulmonary hypertension market.
- Strategic Goal Alignment: This stock option grant aligns with Gossamer Bio's ambition to become an industry leader in pulmonary arterial hypertension treatment, aiming to accelerate product development and market penetration by attracting and retaining key talent.
Gossamer Bio Options Volume Hits 41,590 Contracts, Significantly Above Average
- Active Options Trading: Gossamer Bio's options volume reached 41,590 contracts today, representing approximately 4.2 million shares, which is a significant 88.3% of its average daily trading volume over the past month.
- High Demand Options: Notably, the $7 strike call option expiring on March 20, 2026, saw 22,747 contracts traded today, equating to about 2.3 million shares, indicating a marked bullish sentiment in the market for this stock.
- FTAI Options Activity: Concurrently, FTAI Aviation's options volume stood at 9,598 contracts, approximately 959,800 shares, which constitutes 85.2% of its average daily trading volume over the past month, suggesting rising market interest in this stock as well.
- Demand for Strike Price: The $270 strike call option for FTAI recorded a trading volume of 1,687 contracts today, representing around 168,700 shares, reflecting investors' positive expectations regarding the stock's future performance.
Oppenheimer Optimistic About Favorable PROSERA Trial Results for Gossamer Bio (GOSS) Expected in February 2026
Analyst Ratings: Gossamer Bio Inc. has received a Buy rating from Piper Sandler with a price target of $15, while Oppenheimer raised its target to $12, reflecting confidence in the upcoming PROSERA trial results in February 2026.
Financial Performance: The company reported Q3 2025 revenue of $13.3 million, significantly exceeding estimates, but also posted a net loss of $48.2 million, which was wider than the previous year's loss.
Clinical Trials: Gossamer Bio is advancing its clinical trials, having activated the first site for the Phase 3 SERANATA/PH-ILD trial, with results expected in 2027, and is optimistic about achieving significant improvements in the PROSERA trial.
Investment Perspective: While Gossamer Bio shows potential as an investment, there are suggestions that certain AI stocks may offer better upside potential and lower risk, prompting a recommendation to explore undervalued AI stocks.
Gossamer Bio Grants 200,000 Stock Options to Attract New Employee
- Option Grant: Gossamer Bio's Compensation Committee approved the grant of 200,000 non-qualified stock options to a non-executive employee, aimed at attracting talent and enhancing the company's competitive edge.
- Exercise Price: The options have an exercise price of $3.33 per share, equal to Gossamer's stock closing price on December 5, 2025, ensuring alignment of employee interests with the company's stock performance.
- Vesting Schedule: The options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting in monthly installments, which helps improve employee retention and long-term commitment.
- Strategic Importance: This grant complies with Nasdaq listing rules, indicating Gossamer Bio's commitment to attracting and retaining key talent, aiming to bolster its market leadership in the pulmonary hypertension sector.
Gossamer Bio Reveals Inducement Grant in Accordance with Nasdaq Listing Rule 5635(c)(4)
Stock Option Grants: Gossamer Bio's Compensation Committee approved the grant of non-qualified stock option awards to six non-executive employees, allowing them to purchase a total of 378,996 shares of common stock under the 2023 Employment Inducement Incentive Award Plan.
Exercise Price and Vesting: The options have an exercise price of $2.37 per share, equal to the stock's closing price on November 5, 2025, and will vest over four years, with 25% vesting after one year and the remainder in monthly installments.
Company Focus: Gossamer Bio is a late-stage biopharmaceutical company dedicated to developing and commercializing seralutinib for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Investor Relations Contact: For further inquiries, investors and media can contact Bryan Giraudo, Chief Operating Officer and Chief Financial Officer of Gossamer Bio, via the provided email address.
Gossamer Bio (GOSS) Options Trading Volume Hits 36,131 Contracts, 73.1% of Average Daily Volume
- Active Options Trading: Gossamer Bio Inc (GOSS) recorded an options trading volume of 36,131 contracts today, equivalent to approximately 3.6 million shares, representing 73.1% of its average daily trading volume of 4.9 million shares over the past month, indicating strong market interest in its future performance.
- Put Options Highlighted: Notably, the $2 strike put option expiring on February 20, 2026, saw a significant volume of 12,338 contracts traded today, representing about 1.2 million underlying shares, reflecting investor expectations regarding potential downside risks for GOSS's stock price.
- Novanta Options Activity: Concurrently, Novanta Inc (NOVT) experienced an options trading volume of 3,468 contracts, equivalent to approximately 346,800 shares, which accounts for 72.7% of its average daily trading volume of 476,875 shares over the past month, showcasing ongoing market interest in its stock.
- Call Options Trading: Within NOVT's trading, the $140 strike call option expiring on February 20, 2026, stood out with a trading volume of 1,724 contracts today, representing around 172,400 underlying shares, indicating investor optimism regarding its future price potential.
Gossamer Bio Grants 212,500 Stock Options to Employees Under 2023 Inducement Plan
- Incentive Plan Implementation: Gossamer Bio's Compensation Committee approved the grant of 212,500 non-qualified stock options to three non-executive employees, aimed at attracting talent and enhancing employee loyalty in accordance with Nasdaq Listing Rule 5635(c)(4).
- Option Details: The options have an exercise price of $2.74 per share, equal to the closing price on January 5, 2026, with a ten-year term and vesting over four years, reflecting the company's commitment to long-term employee contributions.
- Employee Incentive Mechanism: By providing stock options upon employee onboarding, Gossamer Bio not only enhances employee engagement but also potentially strengthens team stability, which could drive the company's competitive edge in the pulmonary hypertension market.
- Strategic Goal Alignment: This stock option grant aligns with Gossamer Bio's ambition to become an industry leader in pulmonary arterial hypertension treatment, aiming to accelerate product development and market penetration by attracting and retaining key talent.
Gossamer Bio Options Volume Hits 41,590 Contracts, Significantly Above Average
- Active Options Trading: Gossamer Bio's options volume reached 41,590 contracts today, representing approximately 4.2 million shares, which is a significant 88.3% of its average daily trading volume over the past month.
- High Demand Options: Notably, the $7 strike call option expiring on March 20, 2026, saw 22,747 contracts traded today, equating to about 2.3 million shares, indicating a marked bullish sentiment in the market for this stock.
- FTAI Options Activity: Concurrently, FTAI Aviation's options volume stood at 9,598 contracts, approximately 959,800 shares, which constitutes 85.2% of its average daily trading volume over the past month, suggesting rising market interest in this stock as well.
- Demand for Strike Price: The $270 strike call option for FTAI recorded a trading volume of 1,687 contracts today, representing around 168,700 shares, reflecting investors' positive expectations regarding the stock's future performance.
Oppenheimer Optimistic About Favorable PROSERA Trial Results for Gossamer Bio (GOSS) Expected in February 2026
Analyst Ratings: Gossamer Bio Inc. has received a Buy rating from Piper Sandler with a price target of $15, while Oppenheimer raised its target to $12, reflecting confidence in the upcoming PROSERA trial results in February 2026.
Financial Performance: The company reported Q3 2025 revenue of $13.3 million, significantly exceeding estimates, but also posted a net loss of $48.2 million, which was wider than the previous year's loss.
Clinical Trials: Gossamer Bio is advancing its clinical trials, having activated the first site for the Phase 3 SERANATA/PH-ILD trial, with results expected in 2027, and is optimistic about achieving significant improvements in the PROSERA trial.
Investment Perspective: While Gossamer Bio shows potential as an investment, there are suggestions that certain AI stocks may offer better upside potential and lower risk, prompting a recommendation to explore undervalued AI stocks.
Gossamer Bio Grants 200,000 Stock Options to Attract New Employee
- Option Grant: Gossamer Bio's Compensation Committee approved the grant of 200,000 non-qualified stock options to a non-executive employee, aimed at attracting talent and enhancing the company's competitive edge.
- Exercise Price: The options have an exercise price of $3.33 per share, equal to Gossamer's stock closing price on December 5, 2025, ensuring alignment of employee interests with the company's stock performance.
- Vesting Schedule: The options will vest over four years, with 25% vesting on the first anniversary and the remainder vesting in monthly installments, which helps improve employee retention and long-term commitment.
- Strategic Importance: This grant complies with Nasdaq listing rules, indicating Gossamer Bio's commitment to attracting and retaining key talent, aiming to bolster its market leadership in the pulmonary hypertension sector.
Gossamer Bio Reveals Inducement Grant in Accordance with Nasdaq Listing Rule 5635(c)(4)
Stock Option Grants: Gossamer Bio's Compensation Committee approved the grant of non-qualified stock option awards to six non-executive employees, allowing them to purchase a total of 378,996 shares of common stock under the 2023 Employment Inducement Incentive Award Plan.
Exercise Price and Vesting: The options have an exercise price of $2.37 per share, equal to the stock's closing price on November 5, 2025, and will vest over four years, with 25% vesting after one year and the remainder in monthly installments.
Company Focus: Gossamer Bio is a late-stage biopharmaceutical company dedicated to developing and commercializing seralutinib for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Investor Relations Contact: For further inquiries, investors and media can contact Bryan Giraudo, Chief Operating Officer and Chief Financial Officer of Gossamer Bio, via the provided email address.
